Logo image of BPMC

BLUEPRINT MEDICINES CORP (BPMC) Stock Fundamental Analysis

NASDAQ:BPMC - Nasdaq - US09627Y1091 - Common Stock - Currency: USD

86.09  +0.28 (+0.33%)

After market: 86.09 0 (0%)

Fundamental Rating

3

Overall BPMC gets a fundamental rating of 3 out of 10. We evaluated BPMC against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of BPMC have multiple concerns. BPMC shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BPMC had negative earnings in the past year.
In the past year BPMC has reported a negative cash flow from operations.
BPMC had negative earnings in 4 of the past 5 years.
BPMC had negative operating cash flow in 4 of the past 5 years.
BPMC Yearly Net Income VS EBIT VS OCF VS FCFBPMC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

The Return On Assets of BPMC (-5.69%) is better than 88.73% of its industry peers.
With an excellent Return On Equity value of -22.46%, BPMC belongs to the best of the industry, outperforming 85.39% of the companies in the same industry.
Industry RankSector Rank
ROA -5.69%
ROE -22.46%
ROIC N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
BPMC Yearly ROA, ROE, ROICBPMC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

With an excellent Gross Margin value of 96.04%, BPMC belongs to the best of the industry, outperforming 94.72% of the companies in the same industry.
In the last couple of years the Gross Margin of BPMC has grown nicely.
BPMC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
BPMC Yearly Profit, Operating, Gross MarginsBPMC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

2

2. Health

2.1 Basic Checks

BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BPMC has more shares outstanding
Compared to 5 years ago, BPMC has more shares outstanding
The debt/assets ratio for BPMC is higher compared to a year ago.
BPMC Yearly Shares OutstandingBPMC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BPMC Yearly Total Debt VS Total AssetsBPMC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

BPMC has an Altman-Z score of 1.21. This is a bad value and indicates that BPMC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.21, BPMC is in the better half of the industry, outperforming 69.54% of the companies in the same industry.
A Debt/Equity ratio of 1.15 is on the high side and indicates that BPMC has dependencies on debt financing.
BPMC has a Debt to Equity ratio of 1.15. This is in the lower half of the industry: BPMC underperforms 78.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.15
Debt/FCF N/A
Altman-Z 1.21
ROIC/WACCN/A
WACC11.09%
BPMC Yearly LT Debt VS Equity VS FCFBPMC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

BPMC has a Current Ratio of 2.85. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
BPMC has a Current ratio of 2.85. This is in the lower half of the industry: BPMC underperforms 66.90% of its industry peers.
BPMC has a Quick Ratio of 2.80. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BPMC (2.80) is worse than 65.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.85
Quick Ratio 2.8
BPMC Yearly Current Assets VS Current LiabilitesBPMC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.55% over the past year.
BPMC shows a strong growth in Revenue. In the last year, the Revenue has grown by 103.97%.
Measured over the past years, BPMC shows a very strong growth in Revenue. The Revenue has been growing by 50.23% on average per year.
EPS 1Y (TTM)54.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.59%
Revenue 1Y (TTM)103.97%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%103.41%

3.2 Future

The Earnings Per Share is expected to grow by 34.82% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 28.14% on average over the next years. This is a very strong growth
EPS Next Y68.69%
EPS Next 2Y52.12%
EPS Next 3Y45.23%
EPS Next 5Y34.82%
Revenue Next Year42.93%
Revenue Next 2Y37.27%
Revenue Next 3Y33.57%
Revenue Next 5Y28.14%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BPMC Yearly Revenue VS EstimatesBPMC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
BPMC Yearly EPS VS EstimatesBPMC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BPMC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BPMC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BPMC Price Earnings VS Forward Price EarningsBPMC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPMC Per share dataBPMC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

BPMC's earnings are expected to grow with 45.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.12%
EPS Next 3Y45.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BPMC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (4/24/2025, 8:00:00 PM)

After market: 86.09 0 (0%)

86.09

+0.28 (+0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners106.9%
Inst Owner Change0.03%
Ins Owners0.8%
Ins Owner Change3.07%
Market Cap5.50B
Analysts81.38
Price Target130.03 (51.04%)
Short Float %7.49%
Short Ratio4.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.16%
Min EPS beat(2)-10.05%
Max EPS beat(2)9.73%
EPS beat(4)3
Avg EPS beat(4)15.27%
Min EPS beat(4)-10.05%
Max EPS beat(4)39.24%
EPS beat(8)7
Avg EPS beat(8)14.87%
EPS beat(12)10
Avg EPS beat(12)10.07%
EPS beat(16)12
Avg EPS beat(16)-6.62%
Revenue beat(2)0
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-1.61%
Max Revenue beat(2)-1.07%
Revenue beat(4)2
Avg Revenue beat(4)11.31%
Min Revenue beat(4)-1.61%
Max Revenue beat(4)30.77%
Revenue beat(8)6
Avg Revenue beat(8)16.72%
Revenue beat(12)9
Avg Revenue beat(12)20.69%
Revenue beat(16)12
Avg Revenue beat(16)16.8%
PT rev (1m)0.64%
PT rev (3m)1.51%
EPS NQ rev (1m)3.42%
EPS NQ rev (3m)21.71%
EPS NY rev (1m)-2.91%
EPS NY rev (3m)-24.03%
Revenue NQ rev (1m)-1.04%
Revenue NQ rev (3m)0.23%
Revenue NY rev (1m)0.18%
Revenue NY rev (3m)2.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.81
P/FCF N/A
P/OCF N/A
P/B 18.42
P/tB 18.42
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-3.09
FCFYN/A
OCF(TTM)-3.01
OCFYN/A
SpS7.96
BVpS4.67
TBVpS4.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.69%
ROE -22.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.04%
FCFM N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
F-Score2
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 1.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.42%
Cap/Sales 0.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.85
Quick Ratio 2.8
Altman-Z 1.21
F-Score2
WACC11.09%
ROIC/WACCN/A
Cap/Depr(3y)80.73%
Cap/Depr(5y)67.67%
Cap/Sales(3y)3.9%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.59%
EPS Next Y68.69%
EPS Next 2Y52.12%
EPS Next 3Y45.23%
EPS Next 5Y34.82%
Revenue 1Y (TTM)103.97%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%103.41%
Revenue Next Year42.93%
Revenue Next 2Y37.27%
Revenue Next 3Y33.57%
Revenue Next 5Y28.14%
EBIT growth 1Y56.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.17%
EBIT Next 3Y56.3%
EBIT Next 5Y36.11%
FCF growth 1Y56.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.91%
OCF growth 3YN/A
OCF growth 5YN/A